Pemigatinib, a kinase inhibitor used to treat locally advanced or metastatic, unresectable cholangiocarcinoma in adults by inhibiting FGFR1, FGFR2, and FGFR3, has been approved by the FDA. The gene discussed is FGFR3; the disease is cholangiocarcinoma.